Glenmark Pharma gets tentative USFDA nod for skin treatment drug - World News - Breaking international news and headlines

World News - Breaking international news and headlines

Latest headlines and updates on news from around the world. Find breaking stories, upcoming events and expert opinion, international news, features and analysis from Africa, the Asia-Pacific, Europe, Latin America, the Middle East, South ...

BREAKING

Home Top Ad

Responsive Ads Here

Post Top Ad

Responsive Ads Here

Monday, November 26, 2018

Glenmark Pharma gets tentative USFDA nod for skin treatment drug

Glenmark Pharmaceuticals Monday said it has received tentative nod from the US health regulator for Clobetasol Propionate foam, used to treat inflammation and itching caused by a number of skin conditions like eczema.

Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food & Drug Administration (US FDA) for Clobetasol Propionate Foam, 0.05 per cent (Emulsion Formulation), the company said in a BSE filing.

The approved product is a generic version of Mylan Pharmaceuticals Inc's Olux-E Foam, 0.05 per cent.

Quoting IQVIA sales data for the 12-month period ended September 2018, Glenmark Pharmaceuticals said, Olux-E Foam achieved annual sales of around USD 13.2 million.

The company's current portfolio consists of 144 products authorised for distribution in the US market and 55 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.

Shares of Glenmark Pharmaceuticals were trading 0.06 per cent lower at Rs 637.45 apiece on BSE.  
 

Article Type: 
Sections: 
Agencies: 
Mon, 26 Nov 2018-11:41am
Date updated: 
Monday, 26 November 2018 - 11:41am
Article Images: 
Glenmark
Short URL: 
dnai.in/fMub
Embargo: 
Syndicate: 
Hide lead image: 
Page views: 
16
From Print Edition: 
Highlights: 


from Daily News & Analysis https://ift.tt/2QiFJYz

No comments:

Post a Comment

Post Bottom Ad

Responsive Ads Here

Pages